On September 29, Gelonhui reported that Pacific Shuanglin Bio-Pharmacy (000403.SZ) conducted an investor survey on September 26, 2024 regarding the 'Company's new product research and development plan and goals?' The company stated that the number of products determines the profitability of blood product enterprises, and the company will closely follow market demand and development trends, continuously increase the research and development efforts for new products. In terms of new product research and development, the company currently has more than 10 products in rapid progress. Regarding Guangdong Shuanglin, by the end of 2023, Jiu Indicators has obtained clinical trial approval, and in mid-2024, the fourth generation of Jingde has also obtained clinical trial approval; as for Pacific Pharmaceutical Science, the focus is on accelerating the research and development of the fourth generation of Jingde and the construction of supporting production lines. PCC has obtained clinical trial approval and intends to submit an application for market approval, and the eight indicators are planned to apply for clinical trial approval. In terms of optimizing existing products on the market, the company will combine domestic and international market demand to increase the specifications and indications of existing products, extend their shelf life, improve yield, optimize and reduce production costs, and continuously enhance the product's market competitiveness.